Liver carcinogenesis by FOS-dependent inflammation and cholesterol dysregulation
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
Human hepatocellular carcinomas (HCCs), which arise on a background of chronic liver damage and inflammation, express c-Fos, a component of the AP-1 transcription factor. Using mouse models, we show that hepatocyte-specific deletion of c-Fos protects against diethylnitrosamine (DEN)-induced HCCs, whereas liver-specific c-Fos expression leads to reversible premalignant hepatocyte transformation and enhanced DEN-carcinogenesis. c-Fos–expressing livers display necrotic foci, immune cell infiltration, and altered hepatocyte morphology. Furthermore, increased proliferation, dedifferentiation, activation of the DNA damage response, and gene signatures of aggressive HCCs are observed. Mechanistically, c-Fos decreases expression and activity of the nuclear receptor LXRα, leading to increased hepatic cholesterol and accumulation of toxic oxysterols and bile acids. The phenotypic consequences of c-Fos expression are partially ameliorated by the anti-inflammatory drug sulindac and largely prevented by statin treatment. An inverse correlation between c-FOS and the LXRα pathway was also observed in human HCC cell lines and datasets. These findings provide a novel link between chronic inflammation and metabolic pathways important in liver cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Hoshida, Y., Nijman, S. M. B., Kobayashi, M., Chan, J. A., Brunet, J.-P., Chiang, D. Y., Villanueva, A., Newell, P., Ikeda, K., Hashimoto, M., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1089 · Cited by 1,238 · cited 5×
“, 2007), S1 (Hoshida et al., 2009), the proliferative class (Chiang et al.”
BackgroundMethodResultInfluentialChinetti, G., Lestavel, S., Bocher, V., Remaley, A. T., Neve, B., Torra, I. P., Teissier, E., Minnich, A., Jaye, M., Duverger, N., et al. (2001) · Nature Medicine · doi:10.1038/83348 · Cited by 1,170 · cited 1×
“…decreased LXRα expression and activity in liver cells occurs through direct binding of PPARγ to the LXRα promoter, as shown in human macrophages (Chinetti et al., 2001; Laffitte et al., 2001), or rather, as proposed by Yoshikawa et al. (2003), through competitive reduction of LXR/RXR dimers,…”
BackgroundTranscriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR
Calkin, A. C., & Tontonoz, P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3312 · Cited by 779
Focal Gains of VEGFA and Molecular Classification of Hepatocellular Carcinoma
Chiang, D. Y., Villanueva, A., Hoshida, Y., Peix, J., Newell, P., Minguez, B., LeBlanc, A. C., Donovan, D. J., Thung, S. N., Solé, M., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0742 · Cited by 719
Bile-acid-induced cell injury and protection
Perez, M. J., & Briz, O. (2009) · World Journal of Gastroenterology · doi:10.3748/wjg.15.1677 · Cited by 717
The UCSC Genome Browser database: 2014 update
Karolchik, D., Barber, G. P., Casper, J., Clawson, H., Cline, M. S., Diekhans, M., Dreszer, T. R., Fujita, P. A., Guruvadoo, L., Haeussler, M., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1168 · Cited by 670
Yang, F., Huang, X., Yi, T., Yen, Y., Moore, D. D., & Huang, W. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-1078 · Cited by 488
Fibrosis-dependent mechanisms of hepatocarcinogenesis
Zhang, D. Y., & Friedman, S. L. (2012) · Hepatology · doi:10.1002/hep.25670 · Cited by 444 · cited 1×
“The c-Fos–dependent metabolic alterations are similar to those observed in Lxrα knockout mice (Peet et al., 1998; Zhang and Friedman, 2012).”
ResultSpontaneous hepatocarcinogenesis in farnesoid X receptor-null mice
Kim, I., Morimura, K., Shah, Y., Yang, Q., Ward, J. M., & Gonzalez, F. J. (2007) · Carcinogenesis · doi:10.1093/carcin/bgl249 · Cited by 357 · cited 1×
“Mice lacking FXR have increased BAs, liver damage, inflammation, and late-onset liver tumors, all prevented by restoring BA homeostasis through BA-sequestering agents or intestinal FXR expression (Kim et al., 2007; Yang et al., 2007; Degirolamo et al., 2015).”
BackgroundMedical therapies for hepatocellular carcinoma: a critical view of the evidence
Villanueva, A., Hernandez-Gea, V., & Llovet, J. M. (2013) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.199 · Cited by 314 · cited 2×
“Although some improvement in the management of HCC has been achieved in the last 30 years, beneficial treatment is only possible at early stages by local ablative therapies, resection, or transplantation (Villanueva et al., 2013).”
BackgroundMechanisms for cellular cholesterol transport: Defects and human disease
Ikonen, E. (2006) · Physiological Reviews · doi:10.1152/physrev.00022.2005 · Cited by 229
Degirolamo, C., Modica, S., Vacca, M., Di Tullio, G., Morgano, A., D'Orazio, A., Kannisto, K., Parini, P., & Moschetta, A. (2015) · Hepatology · doi:10.1002/hep.27274 · Cited by 121
Güller, M., Toualbi-Abed, K., Legrand, A., Michel, L., Mauviel, A., Bernuau, D., & Daniel, F. (2008) · World Journal of Gastroenterology · doi:10.3748/wjg.14.6339 · Cited by 52
Cited by
Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities
Huang, B., Song, B.-L., & Xu, C. (2020) · Nature Metabolism · doi:10.1038/s42255-020-0174-0 · Cited by 921
Ioannou, G. N., Lee, S. P., Linsley, P. S., Gersuk, V., Yeh, M. M., Chen, Y., Peng, Y., Dutta, M., Mascarinas, G., Molla, B., et al. (2022) · Hepatology Communications · doi:10.1002/hep4.1858 · Cited by 52
Kaminsky-Kolesnikov, Y., Rauchbach, E., Abu-Halaka, D., Hahn, M., García-Ruiz, C., Fernandez-Checa, J. C., Madar, Z., & Tirosh, O. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/5393761 · Cited by 39
“The expression of c-Fos in hepatocytes in response to the accumulation of cholesterol, oxysterols, and primary bile acids may cause liver inflammation [16].”
BackgroundLiang, J., Wei, J., Cao, J., Qian, J., Gao, R., Li, X., Wang, D., Gu, Y., Dong, L., Yu, J., et al. (2023) · Genome Biology · doi:10.1186/s13059-023-03084-8 · Cited by 27
“On the other hand, Fos deletion had been proved to upregulate metabolic pathways in a liver conditional knockout mouse model [44], which is consistent with our data obtained from the organoid model.”
BackgroundResult
Metadata
- Authors
- Bakiri, L., Hamacher, R., Graña, O., Guío-Carrión, A., Campos-Olivas, R., Martinez, L., Dienes, H. P., Thomsen, M. K., Hasenfuss, S. C., & Wagner, E. F.
- Venue
- Journal of Experimental Medicine
- Publisher
- Rockefeller University Press
- Published
- 2017-03-29
- Volume
- 214
- Issue
- 5
- Pages
- 1387-1409
- ISSN
- 0022-1007 (ISSN-L)
- 1540-9538
- OpenAlex
- W2604023601
- Cited by
- 133
- References
- 14
- FWCI
- 4.77
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.